$ATYR: The FDA Just Cleared aTyr's Second Shot. The Market Values the Company at Less Than Its Bank Account.
aTyr Pharma got FDA alignment on a new Phase 3 for efzofitimod a year after an 83% one-day collapse. At $0.37, below net cash, the next sixty days decide the trade, not the science: a reverse-split vote and a Nasdaq deadline.
One year ago almost to the day, aTyr Pharma had one of the worst single sessions a clinical-stage biotech can have. On Friday, September 12, 2025, the stock closed at $6.03. The following Monday, after the company reported that its Phase 3 EFZO-FIT study in pulmonary sarcoidosis had missed its primary endpoint, it closed at $1.01. An 83% drawdown in one day, and the stock has never been back above $1.10 since.
This morning, the same company announced that the FDA has aligned with it on the protocol for a second Phase 3 study of the same drug, efzofitimod, in the same disease. The stock (Nasdaq: ATYR) nearly doubled in premarket trading, touching $0.73 before giving almost all of it back by the open, and it is sitting on the morning's trending and premarket-gainer lists. It closed Wednesday at $0.375, a market capitalization of about $37 million on 98.1 million shares.
Here is what makes this worth twenty minutes of your attention rather than a scroll-past: at $37 million, the market values aTyr at less than the cash and investments on its own balance sheet. As of June 30, the company held $16.2 million in cash and $41.3 million in short-term investments, a combined $57.4 million, against stockholders' equity of $48.8 million, roughly $0.50 per share in book value. The market is not pricing a drug. It is pricing a liquidation, minus a discount for the money management will spend trying again.
Today's announcement is the company formally announcing that it intends to spend it.
What actually happened today
The press release, filed simultaneously as an 8-K, says the FDA has aligned with aTyr on the design of a new global Phase 3: randomized, double-blind, placebo-controlled, enrolling up to approximately 372 patients with chronic, symptomatic pulmonary sarcoidosis and restrictive lung disease. Patients receive 5.0 mg/kg of efzofitimod or placebo intravenously every three weeks, 17 doses over 54 weeks. The primary endpoint is change in forced vital capacity, a standard measure of lung function, at week 48. Study-related activities are expected to begin in the fourth quarter of 2026.
This was a scheduled catalyst, not a surprise: the FDA review has been running since a Type C meeting in mid-April, with official minutes received in May. But the substance matters, because the new trial is built on the most contested kind of evidence in drug development: a subgroup analysis of a failed study.
In EFZO-FIT, the trial that failed, the primary endpoint was corticosteroid reduction, and on that measure the 5.0 mg/kg arm did about the same as placebo. But in a subgroup of 44 patients with restrictive lung disease, the treated patients showed a placebo-adjusted improvement in forced vital capacity of roughly 124 milliliters, along with improvements across multiple patient-reported outcome measures. The new Phase 3 is that subgroup, promoted to an entire trial: restrictive-disease patients only, FVC as the primary endpoint, the symptom questionnaire as the key secondary.
Sarcoidosis is an inflammatory disease in which immune-cell clusters form in organs, most often the lungs; corticosteroids, with their long tail of side effects, remain the standard of care for the pulmonary form. A drug that demonstrably improved lung function in these patients would matter clinically and commercially. That is the prize. The question the market is weighing at $0.37 is not whether the prize is real. It is whether a company worth less than its own bank account can afford the ticket, and what happens to the share count on the way. The filings, including a shareholder vote scheduled three weeks from now that almost nobody is watching, contain a fairly precise answer.
Get the next briefing free in your inbox: Join AlphaBriefing
The rest of this briefing is for paid members: the balance-sheet clock measured against what a 372-patient trial actually costs, the October 16 shareholder vote and the November 30 Nasdaq deadline that frame the next sixty days, why the financing math all but forces one specific outcome, and scenario-by-scenario price zones.
AlphaBriefing Paid gets you every investment thesis, scenario framework, and catalyst brief we publish, the analysis private intel clients pay four figures for, at a fraction of that.